Skip to main content
. 2021 Sep 8;13(9):1428. doi: 10.3390/pharmaceutics13091428

Figure 9.

Figure 9

In vitro anti-pancreatic cancer effect. PANC-1, BXPC-3, and CFPAC-1 cell viability after treatment by (1) siRNA-Mate/siKras, (2) HAp-PEI/siKras, (3) DEPC H2O, (4) siKras, (5) HAp-PEI, (6) HAp/siKras, and (7) HAp-PEI/siNC for 72 h. Untreated cells were used as control. Values are represented as mean ± SD (n = 3). Statistical significance relative to the group of control: * p < 0.05, ** p < 0.01.